RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Antibe Therapeutics Stock

Antibe Therapeutics ROCE 2024

Antibe Therapeutics ROCE

-0.51

Ticker

ATE.TO

ISIN

CA0370255097

WKN

A2QJPN

In 2024, Antibe Therapeutics's return on capital employed (ROCE) was -0.51, a 13.45% increase from the -0.45 ROCE in the previous year.

Antibe Therapeutics Aktienanalyse

What does Antibe Therapeutics do?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Antibe Therapeutics's Return on Capital Employed (ROCE)

Antibe Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Antibe Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Antibe Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Antibe Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Antibe Therapeutics stock

What is the ROCE (Return on Capital Employed) of Antibe Therapeutics this year?

The ROCE of Antibe Therapeutics is -0.51 undefined this year.

How has the ROCE (Return on Capital Employed) of Antibe Therapeutics developed compared to the previous year?

The ROCE of Antibe Therapeutics has increased by 13.45% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Antibe Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Antibe Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Antibe Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Antibe Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Antibe Therapeutics impact the company?

An increase in the ROCE of Antibe Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Antibe Therapeutics affect the company?

A decrease in ROCE of Antibe Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Antibe Therapeutics?

Some factors that can affect Antibe Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Antibe Therapeutics so important for investors?

The ROCE of Antibe Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Antibe Therapeutics take to improve the ROCE?

To improve the ROCE, Antibe Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Antibe Therapeutics pay?

Over the past 12 months, Antibe Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antibe Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Antibe Therapeutics?

The current dividend yield of Antibe Therapeutics is .

When does Antibe Therapeutics pay dividends?

Antibe Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antibe Therapeutics?

Antibe Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Antibe Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antibe Therapeutics located?

Antibe Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antibe Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antibe Therapeutics from 10/3/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did Antibe Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of Antibe Therapeutics in the year 2023?

In the year 2023, Antibe Therapeutics distributed 0 CAD as dividends.

In which currency does Antibe Therapeutics pay out the dividend?

The dividends of Antibe Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Antibe Therapeutics

Our stock analysis for Antibe Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antibe Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.